Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Corning Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Corning Incorporated trades at $167.38 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 4.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Corning Incorporated pays a 0.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GLW | |
|---|---|---|
Market Cap | $29.60B | $137.12B |
Sector | Health | Technology |
52-Week High | $491.22 | $255.79 |
52-Week Low | $205.48 | $64.52 |
Enterprise Value | $27.56B | $144.00B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Corning (GLW) trades at $167.02, up 5.88% over 24 hours, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS up 30% year-over-year. Revenue growth is accelerating, driven by optical communications and AI data center demand, though valuation multiples remain elevated. Recent news highlights analyst upgrades citing improved fundamentals post-sell-off.
Outlook is positive with a consensus price target of $193.33 (15.8% upside), supported by AI infrastructure growth and profitability improvements. Risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling solar and automotive segments. Institutional sentiment is bullish with 56.75% buy ratings, but technical indicators warn of near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
